A recent study by scientists at Tongji University highlights the potential of TBAJ-587, a novel diarylquinoline, in addressing the challenge of treating Mycobacterium abscessus infections, a subset of nontuberculous mycobacteria that exhibit resistance to many antibiotics.
A paper published May 3 in Nature Communications about a patient infected with Mycobacterium chelonae who was cured by way of bacteriophage treatment sparked more intrigue around how to attack the nontuberculous mycobacteria (NTM) group of bugs that cause lung infections.
